Patients treated with statins have a significant 55% decreased odds of contrast-induced nephropathy.
Increased long-term mortality risk for patients with, but not those without, chronic kidney disease.
Researchers found no statistically significant incidence of CIN in a study of 2,277 patients who had a total of 2,583 CT scans with contrast.
In a study of patients undergoing coronary procedures, the incidence of CIN was 2.7% alprostadl recipients versus 11.1% of controls.
The condition was 67% less likely to develop in patients who received a nitrate before percutaneous coronary intervention.
It might decrease the likelihood of renal function decline, however.
Contrast volume:eGFR ratio may be useful in calculating the maximum amount of contrast to give.
Use of ACE inhibitors and angiotensin receptor blockers during coronary angiography found to independently boost risk by 43%.
PRAGUE—Transient hyponatremia may precede development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography, according to investigators.
LAS VEGAS—Women with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or higher are at higher risk than men for experiencing radiocontrast-induced nephropathy (RCIN) following coronary angiography, investigators reported at the National Kidney Foundation's Spring Clinical Meetings.
CHICAGO—Brazilian researchers report that acetylcysteine should no longer be used to prevent contrast-induced nephropathy (CIN) in patients undergoing coronary and vascular angiography.
Researchers find no difference between saline and sodium bicarbonate.
Contrast-induced nephropathy (CIN) develops in 11% of emergency department patients who undergo contrast-enhanced CT (CECT).
A recent study shows that sodium bicarbonate is no better than saline in preventing contrast-induced nephropathy (CIN).
Evidence comes from a study comparing two strategies for preventing contrast-induced nephropathy
PLC Medical Systems, Inc., of Franklin, Mass., has received full approval for a U.S. pivotal trial to study the effectiveness of its RenalGuard System and associated therapy in the prevention of contrast-induced nephropathy (CIN).